98%
921
2 minutes
20
Epstein-Barr nuclear antigen 1 (EBNA1) is an attractive therapeutic target for identifying pharmaceutical drug molecules to fight Epstein-Barr virus (EBV) contagion because of its key function in viral reproduction. To find potent EBNA1 inhibitors, the Naturally Occurring Plant-based Anticancer Compound-Activity-Target (NPACT) database, including > 1500 compounds, was filtered utilizing computational approaches. The efficiency of the docking technique used to anticipate the inhibitor-EBNA1 binding pose was initially evaluated based on obtainable experimental data. Upon the computed docking scores, molecular dynamics simulations (MDSs) were executed for the most superior NPACT compounds bound to EBNA1, accompanied by binding affinity estimations utilizing the MM/GBSA approach. According to binding affinity computations over 200 ns MDS, bitucarpin A demonstrated stronger Δ than KWG, an EBNA1 reference inhibitor, with values of -39.1 and -32.4 kcal/mol, respectively. Post-MD analyses assured the steadiness of bitucarpin A inside the EBNA1 binding pocket over 200 ns MDS. Besides, pharmacokinetics, physicochemical, and toxicity features were predicted for bitucarpin A and demonstrated its promising oral bioavailability. Density functional theory calculations were executed, and their outcomes substantiated the results given by docking and MDS computations. According to these findings, bitucarpin A showed promising inhibitory activity as a potent EBNA1 inhibitor that may be a prospective anti-EBV drug candidate.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12237558 | PMC |
http://dx.doi.org/10.1155/jotm/1786204 | DOI Listing |
J Trop Med
July 2025
Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, Mainz 55128, Germany.
Epstein-Barr nuclear antigen 1 (EBNA1) is an attractive therapeutic target for identifying pharmaceutical drug molecules to fight Epstein-Barr virus (EBV) contagion because of its key function in viral reproduction. To find potent EBNA1 inhibitors, the Naturally Occurring Plant-based Anticancer Compound-Activity-Target (NPACT) database, including > 1500 compounds, was filtered utilizing computational approaches. The efficiency of the docking technique used to anticipate the inhibitor-EBNA1 binding pose was initially evaluated based on obtainable experimental data.
View Article and Find Full Text PDFFront Chem
April 2025
Honam Regional Center, Korea Basic Science Institute (KBSI), Gwangju, Republic of Korea.
Background: Breast cancer (BC) remains a leading cause of cancer-related mortality in women. The oncoprotein MDM2 negatively regulates the tumor suppressor p53, and its overexpression in BC promotes tumor progression and resistance to therapy. Targeting the MDM2-p53 interaction represents a promising therapeutic approach.
View Article and Find Full Text PDFChem Biodivers
June 2025
Department of Pharmaceutical Chemistry, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu, India.
Maternal embryonic leucine zipper kinase (MELK), a pivotal signaling protein, plays a crucial role in various physiological processes, such as cell growth, survival, and differentiation. There is currently a growing interest in MELK as a promising therapeutic target for multiple cancers, including triple-negative breast cancer (TNBC). Exploring MELK as a target offers a prospective strategy to impede cancer progression and enhance the efficacy of conventional anticancer therapies.
View Article and Find Full Text PDFCurr Comput Aided Drug Des
January 2025
Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II, Institutional Area, Greater Noida, 201306, Uttar Pradesh, India.
Introduction: Squamous cell carcinoma is a major public health concern, with traditional treatments such as surgery, chemotherapy, and radiation therapy frequently resulting in significant side effects. Immunotherapy targeting checkpoints such as PD-1, CTLA-4, and B7- H3 provides a more specific approach but incurs high costs due to monoclonal antibodies.
Aim And Objective: This study aims to investigate the potential of natural flavonoids as lowtoxicity, small molecule-based alternatives targeting the PD-1 immunological checkpoint for SCC treatment.
Heliyon
December 2024
Department of Public Health, University of Health Sciences, Lahore, Pakistan.
Glioblastoma (GBM) is one of the most malignant forms of cancer with the lowest survival ratio. Our study aims to utilize an integrated bioinformatic analysis to identify hub genes against GBM and explore the active phytochemicals with drug-like properties in treating GBM. The study employed databases of DisGenet, GeneCards, and Gene Expression Omnibus to retrieve GBM-associated genes, revealing 142 overlapping genes.
View Article and Find Full Text PDF